Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Dec 26, 2014
HCV Competition Not New “News” for Gilead
Gilead is trading more than 40% above its 52-week low and about 20% from its 52-week high. We see no reason to panic, and the company’s trading activity more closely reflects a company whose stock price has quintupled in recent years than one that is in any trouble whatsoever. Gilead’s shares bounced right off technical support levels, and we see a long term that is still very bright for the biotech. Gilead’s shares remain underpriced even under a bear-case scenario. Jun 26, 2013
Weak Food Sales Spoil Walgreens’ Third Quarter
Walgreens suffered from weak front-end same-store sales growth during its third quarter. Did Tuesday’s fall provide an entry point? Jun 4, 2013
Evaluating the Industry Structure of Managed Care Organizations
We take a look at the managed care organization (MCO) and health insurance/benefits industry. We're comfortable being on the sidelines. Dec 10, 2012
FAQ: How Often Does Valuentum Make Changes To Its Actively-Managed Portfolios?
We answer one of the most important questions behind the success of our process. Sep 28, 2012
Sales Slip at Walgreen
Though the firm struck a deal with Express Scripts, Walgreen continues to struggle. We aren't interested in the shares, despite its strong dividend-growth profile. Jun 21, 2012
Walgreen’s Investment in Alliance Boots is Baffling
Walgreen's investment and possible purchase of Alliance Boots is somewhat baffling to us. We dig into why. Sep 28, 2011
Walgreens' Strong Fourth-Quarter Report Overshadowed By Fall Out with Express Scripts
We think Walgreens' contract dispute with Express Scripts doesn't bode well for industry dynamics long term. Medco could be next. We remain on the sidelines. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
